Coronavirus Disease 2019
62
2
3
32
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.8%
3 terminated out of 62 trials
91.4%
+4.9% vs benchmark
13%
8 trials in Phase 3/4
28%
9 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (62)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Study of Varespladib in Patients Hospitalized With Severe COVID-19
Follow-up of Covid-19 Long Term Sequelae
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura
LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III